Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Data spans immunotherapy (IO) response prediction and genomic landscaping in colorectal cancer (CRC), breast cancer, and gynecological cancers

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL.

Highlights from AACR include:

• An oral presentation titled “Large-scale Genomic Profiling of Colorectal Cancer” from an exploratory analysis examining the characteristics of the mutational landscape of CRC and patterns across clinical and molecular subgroups. The study was performed using Natera’s proprietary real-world database (RWD) that comprises de-identified clinical and genomic data from over 73,000 patients who underwent commercial Signatera™ testing.

• Poster presentations exploring the genomic landscape in over 30,000 breast cancer patients and over 8,000 gynecologic cancer patients, revealing distinct genomic patterns, and underscoring the research value of Natera’s RWD.

• Data that integrates Natera’s clinical and genomic information, demonstrating how its real-world evidence database can enhance immunotherapy response prediction by improving neoantigen identification.

• Further datasets in esophageal cancer, sarcoma, and CRC, adding to the evidence base of Signatera’s clinical validity and utility.

“We are pleased to share such a broad set of data showcasing our breadth of capabilities in oncology,” said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer. “In addition to presenting Signatera data in several types of cancer, we look forward to presentations that leverage the use of our multi-modal database of real-world evidence, which can provide valuable insights to strengthen drug discoveries and potentially accelerate therapeutic breakthroughs.”

About Signatera

Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers.

About Natera

Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 250 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.